Search for Clinical Trial Results
Respiratory Syncytial Virus Infections - 28 Studies Found
Status | Study |
Completed |
Study Name: Safety Study of Oral BTA9881 to Treat RSV Infection Condition: Respiratory Syncytial Virus Infections Date: 2007-07-18 Interventions:
|
Terminated |
Study Name: Ribavirin to Prevent RSV Pneumonia in Bone Marrow Transplant Patients Condition: Respiratory Syncytial Virus Infections Date: 2002-03-06 Interventions: Drug: Virazole (Ribavirin) Inhalation Solution |
Completed |
Study Name: Innate Immunity and Respiratory Syncytial Virus (RSV) Infection in Children Condition: Respiratory Syncytial Virus Infection Date: 2008-01-03 |
Completed |
Study Name: A Study of the Safety and Efficacy of A-60444 in Adults With Respiratory Syncytial Virus (RSV) Infection Following HSCT Condition: Respiratory Syncytial Virus Infections Date: 2005-10-04 Interventions: Drug: A-60444 |
Active, not recruiting |
Study Name: Study to Evaluate the Efficacy and Safety of REGN2222, for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants Condition: Respiratory Syncytial Virus Infections Date: 2014-12-21 Interventions:
|
Completed |
Study Name: Respiratory Syncytial Virus Infection in Neonatal Intensive Care Units Throughout Turkey: Prospective Multicenter Study (TurkNICU-RSV Trial) Condition:
|
Completed |
Study Name: Clinical Study of Palivizumab in Japanese Newborns, Infants and Young Children at the Age of 24 Months or Less With Immunocompromised Medical Conditions Condition: Respiratory Syncytial Virus Infection Date: 2011-09-12 Interventions: Drug: Palivizumab Other Names:
|
Completed |
Study Name: ALX-0171 Safety Study in Adults With Hyperresponsive Airways Condition: Respiratory Syncytial Virus Infection Date: 2013-07-24 Interventions: Biological: ALX-0171 Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maxim |
Completed |
Study Name: Surveillance of Synagis in Korean Pediatric Patients Condition: Respiratory Syncytial Virus Infection Date: 2011-12-15 |
Recruiting |
Study Name: Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age Condition: Respiratory Syncytial Virus Infections Date: 2017-03-23 Interventions:
|